NEW YORK (GenomeWeb News) – The investors in Cellexus Ltd. said yesterday that they have acquired the assets of Cellexus Biosystems Plc and have formed a new management team aimed at bringing the firm’s products to market.
Cellexus makes single-use bioreactors and cell-based technologies for biopharmaceutical research and production. The firm said that since the asset acquisition it has “made significant design and operational improvements to the CellMaker bioreactor systems.”
It also intends to launch a range of new products over the coming months including the CellMaker Regular for culture of E. Coli and Pichia cells and the CellMaker PLUS for culture of all cells including mammalian and insect.
The Cambridgeshire, UK-based company said that it made the purchase in April, but did not disclose it until this week.